C oronary artery disease (CAD) has multifactorial origins, and although some families are particularly affected, no precise mode of inheritance has been identified. It is likely that this reflects the contribution of numerous genetic components, each conferring a small risk in cumulative interaction with environmental factors to substantively increase disease susceptibility. 1 In recent years, significant advances have been made in elucidating the genetic basis of CAD with the completion of several large genome-wide association studies (GWAS) that have looked at the DNA variation across the entire human genome. In a landmark study in 2007, the Wellcome Trust Case Control Consortium identified a region on chromosome 9 (9p21.3) that was the most strongly associated with the risk of developing CAD, 2 a finding that has since been replicated in several independent studies. [3] [4] [5] [6] The 9p21.3 rs1333049 variant is common and may potentially be added to risk profiling in the future. Already it has been reported that adding the 9p21.3 genotype to the traditional risk score significantly improves CAD risk prediction in the community. 7 
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The second most replicated region for risk of CAD is a locus at 1p13. A variant within this region, rs599839, is associated with less risk of both CAD and myocardial infarction (MI) 2,5,8 -11 ; lower levels of low-density lipoprotein (LDL), LDL triglycerides, and apoB; and an increased radius of LDL particles. 10 -13 A genomic region at 1q41 has also been identified as a strong genetic predictor of CAD. Within 1q41, rs17465637, which lies within the melanoma-inhibitory family member gene (MIA3), has been identified as the strongest signal. 2, 8, 14, 15 Although early GWAS have been successful in identifying the chromosomal regions most significantly associated with CAD (including 9p21.3, 1p13.3, and 1q41), important regions with more modest effects or lower allele frequencies may have been missed. More recently, a second wave of studies has focused on these "smaller" signals, including a locus at 3q22.3 within MRAS. 14 Within 3q22.3, the most highly associated gene variant rs9818870 is located in the 3Ј untranslated region of MRAS and is in proximity to a cluster of regulatory miRNA binding sites. 14 In recent years, GWAS have generated a wealth of information on genetic susceptibility to CAD. Some regions are now predictive of incident CAD; however, whether these genetic risk regions influence disease progression in patients with established CAD remains largely unknown. Previously, we have reported that a common risk variant within the 9p21.3 risk region was associated with age of CAD onset but not subsequent mortality. 16 In the current study, we have investigated the association between risk variants at 1p13.3, 1q41, and 3q22.3 and cardiovascular outcomes in both individuals free of overt cardiovascular disease (CVD) at the time of recruitment and in patients with established CAD.
Methods

Study Participants
Canterbury Healthy Volunteers Study
Volunteers randomly selected from the Canterbury electoral roll and age and sex matched to existing patient cohorts were recruited into the Canterbury Healthy Volunteers study (HV) (nϭ1649). Participants were aged 20 to 108 years. Study participants were screened before recruitment using hospital Patient Management Systems (PMS) databases and had no personal history of overt CVD, including CAD, MI, or peripheral vascular disease. Participants completed a study questionnaire on their medical history, smoking status, alcohol consumption, and self-reported physical activity. Height, weight, waist, and hip measurements were taken. Blood pressure was recorded, and a blood sample was taken for neurohormone and genetic analyses. Median follow-up was 5.9 years (range, 0.1-8.7 years). Study participants were followed through PMS and New Zealand Health Information Services (NZHIS) databases. All admissions identified as cardiovascular were confirmed by clinical review at the time of discharge. Admissions that were determined to be noncardiac were excluded. The diagnosis at each hospital admission was defined using the ICD-10 (International Classification of Diseases and Related Health Problems, 10th Revision). The study was approved by the Upper South A Ethics Committee (Reference No. CTY/01/05/062), and each participant provided written, informed consent.
Coronary Disease Cohort Study
From July 2002, patients (nϭ1794) admitted to either Christchurch Hospital or Auckland City Hospital, New Zealand, were recruited into the study. Inclusion criteria were ischemic discomfort plus 1 or more of the following: ECG changes (ST-segment depression or elevation of at least 0.5 mm, T-wave inversion of at least 3 mm in at least 3 leads, or left bundle branch block), elevated levels of cardiac markers, a history of coronary disease, or Ն64 years of age in patients with diabetes mellitus or vascular disease. Patients were excluded from the study if they had a severe comorbidity that limited their life expectancy to Ͻ3 years. Within the Coronary Disease Cohort Study (CDCS) cohort, unstable angina accounted for 26.1% of all diagnoses at discharge, non-ST-segment elevation MI (NSTEMI) for 51.2%, and ST-segment elevation MI (STEMI) for 22.7%. Anthropometric and clinical characteristics were recorded at planned follow-up clinic visits at baseline, 4 months, and 12 months after admission. Clinical events were recorded from questionnaires, patient notes, and NZHIS and hospital PMS databases. Median follow-up was 3.7 years (range, 0.1-7.9 years). The study conformed to the principles outlined in the Declaration of Helsinki and Title 45, US Code of Federal Regulations, Part 46, and was approved by the New Zealand Multi-region Ethics Committee (Reference No. CTY/ 02/02/018). Each participating patient provided written, informed consent.
Post-Myocardial Infarction Study
From November 1994, patients were recruited into the Christchurch Post-Myocardial Infarction (PMI) study (nϭ905). Acute MI (including STEMI and NSTEMI) was defined by the presence of typical cardiac ischemic symptoms, ischemic change on the ECG in 2 or more contiguous leads, and peak elevation of plasma creatine kinase to at least twice normal (400 U/L). Although there were no specific exclusion criteria, the inclusion criteria included age Ͻ80 years, absence of cardiogenic shock, and survival for at least 24 hours after MI. Although this was not an inclusion criterion, all patients were positive for troponin-T. Patients were followed over a median 11.3 years (range, 0 -15.9 years). Subsequent cardiovascular events were determined by clinical review at the time of discharge and were recorded from PMS and NZHIS databases. The study was approved by the Canterbury Ethics Committee (Reference No. CTY/94/08/ 783), and each participating patient provided written, informed consent.
Neurohormone Measurement and Echocardiography
Neurohormone Measurement
For the CDCS cohort, baseline samples and measurements were obtained between 5 and 56 days from the date of index admission. In PMI study participants, blood samples were taken between 24 and 96 hours after the onset of symptoms in the morning (between 0700 and 1300 hours) from an indwelling intravenous cannula placed at least 30 minutes before sampling and with the patient resting quietly while semirecumbent. For each study, blood was collected into chilled EDTA tubes and stored on ice. Plasma was separated within 20 minutes by centrifugation and stored at Ϫ80°C. Plasma was assayed for B-type natriuretic peptide 17 and N-terminal pro-B-type natriuretic peptide. 18 
Echocardiography
Transthoracic echocardiography was performed for CDCS and PMI patients using a GE Vivid 3 ultrasound system (GE Medical Systems; Waukesha, WI) at Christchurch Hospital and an ATL HDI 5000 (Philips Healthcare; Andover, MA) at Auckland City Hospital. The standardized imaging protocol included apical 4-and 2-chamber views according to the American Society of Echocardiography. 19 Parasternal and short-and long-axis views (averaged over 4 cycles) were obtained for M-mode measurements of left ventricular (LV) dimensions. Biplane diastolic and systolic volumes and ejection fraction were calculated by planimetry according to the Simpson method.
DNA Extraction and Genotyping Assays
DNA was extracted from whole blood as previously described. 20 Participants were genotyped for rs599839, rs9818870, and rs17465637 in 5-L reaction volumes using allele-specific TaqMan genotyping probes (Applied Biosystems; Carlsbad, CA) and 100 ng of genomic DNA. Twenty-five percent of samples were reassayed and were 99% concordant with the original genotype calls. Samples for which concordance was not obtained were excluded from the study.
Statistical Analyses
For each single-nucelotide polymorphism (SNP), we identified the genetic model (dominant, additive, or recessive) based on the model that showed the strongest and most consistent associations with baseline patient characteristics and cardiovascular outcomes across all 3 cohorts. As a result, associations between rs599839, rs9818870, and rs17465637 and baseline patient characteristics were reported for a dominant genetic model. For genotype associations with continuous variables, regression coefficients (b) and 95% CIs were determined, and for discrete variables, odds ratios (ORs) and 95% CIs were reported. Hormone data exhibited a skewed distribution and were log-transformed before analysis. The primary end point was the composite end point death and/or readmission to the hospital for a CVD event. The CVD diagnoses combined into this composite outcome measure included unstable angina, STEMI, NSTEMI, heart failure, ischemic stroke, and hemorrhagic stroke. Secondary associations between genotype and readmission for NSTEMI (the most common readmission event type) were explored, as was the association with cardiovascular event rate.
The association between each polymorphism and outcome was assessed using Kaplan-Meier survival analyses and the log-rank test statistic. If significant associations were observed in univariate Kaplan-Meier survival analyses, Cox proportional hazards multivariate analysis was performed to test for independent genotype associations. To increase precision by reducing the residual variation and increasing the power to detect SNP associations, these analyses adjusted for established predictors of increased risk. Where the data allowed, the same covariates were included for each outcome, cohort, and SNP to ensure consistency among models. The established predictors of risk included in multivariate analyses were as follows:
• CDCS and PMI cohorts: age of disease onset, sex, ethnicity, history of MI, history of hypertension, history of high cholesterol, history of type 2 diabetes, history of heart failure, ␤-blocker treatment, smoking status, body mass index, estimated glomerular filtration rate, LV ejection fraction, and N-terminal pro-B-type natriuretic peptide.
• HV cohort: age, sex, ethnicity, hypertension, high cholesterol, and smoking status.
Interestingly, LV ejection fraction was not a significant predictor of outcome in multivariate survival analysis. However, when entered into a model on its own, LV ejection fraction was a significant predictor of death/CVD readmission in both the CDCS (OR, 0.99; 95% CI, 0.98 -0.99; Pϭ1.0ϫ10 Ϫ8 ) and the PMI (OR, 0.99; 95% CI, 0.98 -1.00; Pϭ0.002) cohorts, suggesting that it is not independent of or as strong a prognostic marker as other established predictors of increased risk (eg, N-terminal pro-B-type natriuretic peptide).
Diagnoses at each readmission were defined using the ICD-10. Outcome data were obtained from NZHIS and hospital PMS databases. The power of this study to assess the relationship between genotype and cardiovascular outcomes was estimated assuming 80% power and 2-tailed ␣ϭ0.05. Adopting a conservative approach, this resulted in power to detect a hazard ratio of Յ1.54 in the HV cohort, Յ1.47 in the CDCS cohort, and Յ1.90 in the PMI cohort as being statistically significant. Analyses were performed using PASW version 18.0 (SPSS Inc; Chicago, IL) statistical software.
Results
Baseline Cohort Characteristics and Genotype Frequencies
Baseline characteristics of each cohort are shown in Table 1 and genotype frequencies in Table 2 . There was a significant Table 4 ). The genotype-related differences in these indicators of cardiac structure and function remained significant at both 4 months and 12 months postrecruitment into the study (Pϭ0.001-0.042) (data not shown).
Consistent with these findings, PMI patients carrying the AG/GG genotypes had reduced total cholesterol (bϭϪ0.32; 95% CI, Ϫ0.55 to Ϫ0.11; Pϭ0.004) and LDL cholesterol (bϭϪ0.20, 95% CI, Ϫ0.39 to Ϫ0.02; Pϭ0.031) and significantly smaller LV internal dimension in systole (bϭϪ0.18; 95% CI, Ϫ0.31 to Ϫ0.05; Pϭ0.008) and diastole (bϭϪ0.14; 95% CI, Ϫ0.26 to Ϫ0.02; Pϭ0.024) and LV end-diastolic (bϭϪ8.83; 95% CI, Ϫ16.11 to Ϫ1.55; Pϭ0.018) and endsystolic (bϭϪ7.37; 95% CI, Ϫ12.92 to Ϫ1.81; Pϭ0.009) volumes compared with those carrying the AA genotype after adjustment for age, sex, and ethnicity (Table 5 ). In addition, PMI AG/GG carriers were, on average, older when recruited into the study (bϭ1.58; 95% CI, 0.06 -3.11; Pϭ0.042). There were no significant differences in 1p13.3 genotype frequency with sex, ethnicity, or pharmacotherapy in the CDCS and PMI cohorts; however, HV participants carrying the minor 'G' allele were more likely to be treated with a statin (Pϭ0.0002).
rs17465637 A/C (1q41)
Although there were no consistent associations between 1q41 (rs17465637) genotype and baseline patient characteristics across the cohorts, univariate analyses revealed that PMI 1q41 A allele carriers had higher measured systolic blood pressure (bϭ2.56; 95% CI, 0.32-4.80; Pϭ0.025), and fewer such carriers had dyslipidemia (OR, 0.71; 95% CI, 0.53-0.95; Pϭ0.021) ( Table 5 ). There were no associations between 1q41 and baseline cohort characteristics in the HV or CDCS cohorts (Tables 3 and 4) . No difference in 1q41 genotype frequency with sex or ethnicity were observed; however, in the PMI cohort, 1q41 'A' allele carriers were less likely to be treated with a lipid-lowering drug (Pϭ0.024).
rs9818870 C/T (3q22.3)
In the CDCS cohort, associations were found between the 3q22.3 rs9818870 T allele and a greater age at the time of recruitment to the cohort (bϭ1.94; 95% CI, 0.69 -3.19; Pϭ0.002) and higher high-density lipoprotein cholesterol (bϭ0.10; 95% CI, 0.02-0.18; Pϭ0.019) ( Table 4 ). In the PMI cohort, the 3q22.3 T allele was associated with greater total cholesterol (bϭ0.28; 95% CI, 0.05-0.50; Pϭ0.016) ( Table 5 ). There were no associations between 3q22.3 genotype and HV and PMI baseline characteristics (Tables 3 and  5 ). No significant difference in pharmacotherapy was observed in the HV and PMI cohorts; however, in the CDCS cohort, fewer T allele carriers were treated with a statin (Pϭ0.008). The T allele was more common in HV male than female participants (Pϭ0.009) and occurred at a lower frequency in CDCS participants of Maori/Pacific Island ancestry (Pϭ0.039).
Associations Between Genotype and Cardiovascular Outcomes
Throughout follow-up, the number of participants experiencing a CVD event for each cohort were as follows: HV cohort, 6.2% (nϭ100) died and 12.8% (nϭ207) were admitted for a CVD event, 0.8% (nϭ13) for unstable angina, 2.6% (nϭ42) for NSTEMI, 0.8% (nϭ13) for STEMI, 1.6% (nϭ26) for heart failure, 1.4% (nϭ22) for ischemic stroke, and 0.5% (nϭ8) for hemorrhagic stroke; CDCS cohort, 16.2% (nϭ347) died and 61.5% (nϭ1314) were readmitted for a CVD event, 17.1% (nϭ377) for unstable angina, 22.0% (nϭ470) for NSTEMI, 5.5% (nϭ117) for STEMI, 16.1% (nϭ345) for heart failure, 3.3% (nϭ70) for ischemic stroke, and 0.9% (nϭ19) for hemorrhagic stroke; and PMI cohort, 16 .2% (nϭ327) died and 76.0% (nϭ687) were readmitted for a CVD event, 25.9% (nϭ234) for unstable angina, 16.3% (nϭ147) for NSTEMI, 29.4% (nϭ266) for STEMI, 20.6% (nϭ186) for heart failure, 5.3% (nϭ480) for ischemic stroke, and 1.4% (nϭ13) for hemorrhagic stroke. The average number of CVD admissions for HV participants was 0.19 (range, 0 -13 admissions). CDCS patients were readmitted an average of 2.09 times (range, 0 -30 readmissions), and PMI patients were readmitted an average of 2.57 times (range, 0 -40 readmissions) throughout the follow-up.
rs599839 A/G (1p13.3)
Within the CDCS cohort, the 1p13.3 rs599839 'G' allele was associated with a reduced risk of readmission for NSTEMI (log-rank Pϭ0.012) ( Figure 1 ) and a lower CVD readmission event rate (AA, 0.55 events/person per year; AG/GG, 0.49 events/person per year; Pϭ0.003). The association with NSTEMI was independent of established predictors of increased risk (OR, 0.75; 95% CI, 0.57-0.99; Pϭ0.044) (online-only Data Supplement Table I ). There were no associations between 1p13.3 genotype and cardiovascular outcomes in the HV and PMI cohorts.
rs17465637 A/C (1q41)
Within the PMI cohort, 1q41 was associated with survival/ readmission, with the A allele conferring a protective effect (log-rank Pϭ0.008) (Figure 2 ). The association with outcome was independent of established risk predictors (OR, 0.72; 95% CI, 0.54 -0.96; Pϭ0.024) (online-only Data Supplement Table II) . Consistent with this, in the HV cohort, rs17464637 was associated with admission for NSTEMI (log-rank Pϭ0.028) (Figure 3 ). Fewer study participants carrying the AC/AA genotypes were admitted for NSTEMI throughout follow-up than those carrying the CC genotype. There were no associations between 1q41 and cardiovascular outcomes in the CDCS cohort.
rs9818870 C/T (3q22.3)
In the HV cohort, a significant association between 3q22.2 and survival/admission was observed (log-rank Pϭ0.045) (Figure 4 ). Those participants carrying 1 or more T allele were more likely to have died or experienced a CVD event than those with the CC genotype. Cox proportional hazards analysis revealed that the association between 3q22.3 and survival/admission was independent of established predictors of increased risk (OR, 1.30; 95% CI, 1.01-1.70; Pϭ0.043) (online-only Data Supplement Table III ). There were no significant associations between 3q22.3 and cardiovascular outcomes in either the CDCS or the PMI patient cohorts.
Discussion
In recent years, GWAS have made significant advances in identifying chromosome loci associated with the genetic risk of CAD. However, once CAD is established, whether these variants are associated with greater disease progression and poorer outcomes remains largely unknown. The present data suggest that gene variants within the genomic risk loci at 1p13.3, 1q41, and 3q22.3 previously associated in GWAS with the risk of developing CAD may also be associated with subsequent cardiovascular outcomes, including mortality and hospital admission for CVD events in established heart disease. In addition, we confirmed previously diagnosed associations between 1p13.3 and cholesterol and between 3q22.3 and increased risk of CAD in a prospective study of individuals without previous heart disease. These findings suggest that some genomic risk variants not only may be important risk factors for CAD development, but also may influence disease progression once CAD is established.
The 1p13.3 variant rs599839, located in a large 97-kb block of fragmented disequilibrium, has been associated with a significant reduction in CAD and MI risk in several studies, and a 41% reduction of CAD risk has been reported when comparing GG with AA homozygotes. 2,5,8 -10 In the current study, we confirmed previous associations among the rs599839 G allele, lipid levels, and MI in both patients with CAD and healthy controls. 2,5,8 -13 We also observed significant differences in cardiac function with the 1p13.3 genotype, with less LV remodeling observed in patients carrying the rs599839 G allele. Moreover, in the CDCS cohort, G allele carriers were less likely to experience a subsequent NSTEMI during follow-up, independent of established predictors of risk, and had a lower CVD event readmission rate over a median of 3.7 years follow-up.
The genomic region at 1p13.3 contains 4 genes: proline/ serine-rich coiled protein 1 (PSRC1), cadherin EGF LAG sevenpass G-type receptor 2 (CELSR2), myosin-binding protein H-like (MYBHL), and sortilin 1 (SORT1). Although 4 genes are located within the 1p13.3 locus, SORT1 has emerged as the most likely candidate causal gene. SORT1 is a transmembrane protein receptor that binds a variety of ligands and is involved in the endocytosis and degradation of lipoprotein lipase, a rate-limiting enzyme for the hydrolysis of triglycerides in lipoproteins. 21 More recently, sortilin has been connected to the endocytosis of apoA-V-containing chylomicrons. 22 Because LDL plays a causal role in the development of CVD, it has been hypothesized that increased sortilin expression in G allele carriers leads to greater LDL tissue uptake, which results in reduced circulating LDL levels and, subsequently, a lower CAD risk. 23 However, because most studies have demonstrated only a modest reduction in LDL cholesterol in GG homozygotes, it is likely that this does not fully explain the significant reductions in CAD risk that have been observed.
Chromosome 1q41 (rs17465637) has been associated with CAD and MI in multiple GWAS, with the more frequent C allele increasing CAD risk by Ϸ14%. 5, 8, 14, 15 In the current study, an independent association was observed with survival/readmission in the PMI cohort, and significantly fewer HV participants carrying AC/CC experienced an NSTEMI throughout follow-up compared with CC carriers. The variant rs17465637 lies in intron 4 of the melanoma inhibitory activity family member 3 gene (MIA3). MIA3 has a number of important biological functions and is linked to collagen processing and collagen VII secretion, factors that are critically involved in the response to cardiovascular injury. 24 Early GWAS tended to focus on just a few chromosomal regions (including 9p21.3 and 1p13) with the strongest signals. The genomic risk locus at 3q22.3 was identified in a GWAS for MI using a less stringent cutoff for association. 14 Within this genomic locus, SNP rs9818870 was identified as the lead SNP, with the C allele conferring an increased risk of 15% for CAD.
In the current study, we observed an association between 3q22.3 and death/admission for a CVD event in the HV cohort. Although participants within this study were free of overt CVD at the time of recruitment, carriers of the 3q22.3 rs9818870 T allele were more likely to have died or experienced a CVD event during the follow-up period. These participants also experienced a greater CVD readmission rate than AA individuals.
The lead SNP rs9818870 within 3q22.3 is located in the 3Ј untranslated region of MRAS and is near a cluster of miRNAbinding sites. MRAS is approximately 33 kb in length and contains 5 exons. Studies in mice have demonstrated that M-ras is involved in tumor necrosis factor-␣-stimulated LFA-1 activation in splenocytes, suggesting that M-ras could play a role in the atherosclerosis process through adhesion signaling. 25 The M-ras protein is broadly expressed in tissues and occurs at high levels in the cardiovascular system, particularly in the heart.
The main limitation of the current study is the potential for type 1 error because of multiple comparisons. However, this was not a screening study of newly identified SNPs; we were in the main testing SNPs that have previously been robustly associated with the risk of CVD and its associated disorders in large international cohorts. In addition to confirming many of these previous findings, this study tested the next logical phase in establishing the risk of these SNPs on cardiovascular outcomes in both healthy controls and patients with established coronary heart disease.
The independent association between both 1p13.3 (rs599839) and 1q41 (rs17465637) with cardiovascular outcomes in patients with coronary heart disease suggests that these risk loci may influence disease progression once CAD is established. For SNP rs599839, the association with outcome may be explained in part through protection against adverse LV remodeling. The association between rs9818870 and the primary end point of death/admission for a CVD event in the HV cohort confirms 3q22.3 as a predictor of cardiovascular risk in individuals free of overt heart disease. Further work is required to elucidate the mechanisms by which these regions contribute to the development of CAD.
